Status migrainosus inpatient treatment with eptinezumab (SMITE): study protocol for a randomised controlled trial.

ABSTRACT:

Introduction

Status migrainosus is a disabling complication of migraine, which frequently results in hospitalisation. For patients who fail to respond to simple analgesia, triptans and intravenous prochlorperazine or chlorpromazine, there are limited treatment options, and a paucity of high-quality evidence to guide clinical practice. Eptinezumab, an intravenous monoclonal antibody specific for the calcitonin gene-related peptide ligand which achieves maximal plasma concentration immediately following administration and may improve migraines from day one. Intravenous lignocaine is an anaesthetic medication used in treatment of status migrainosus, often requiring prolonged admissions and with potential cardiac adverse events. The aim of this study is to assess the efficacy and safet

SUBMITTER: Ray JC 

PROVIDER: S-EPMC8905943 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature